““””“”200433.333.533.635.938.944.244.645+52108.6()“”qqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq——qqqqqqqqq“”GenomeI-IVQCmonitoraudit/976SOPs3877inspectorSFDA/FDA““””0109(21)028430359092614677101826133GLP1.2.3./4.5.DNA6.7.8.9.1.2.3.4.5.6.7.8.9.10.11.0.5-1.0g/L0.5-1.0g/L5-50mg/L/2-5L2-20L2001200-300L50-75L10,000L500L2004CellBiolInt,28(3):185-191,2004200410091775.0nnnnnnn“‘·’”nnnnnnnnnnnnnnnn200310113014203283101029092229481621017221086203122563124410419539524321462611(%)(%)()n80%n2003400253185.7%14.3%3616:12000“”NasdaqbioTechindex43%,Burrillbiotechselectindex66%.,2003FDA25.FDARituxanHerceptinMylotargZevalinOrthocloneZenapaxSimulectReoproSynagisRituxanHerceptinSynagis101.Fundamentalscience2.RNAi()3.Vaccicesandantivirals4.Cancerdrugs(gene-basedHerceptin,Iressa,Rituxan)5.Memory(memantineCAMP)1.Genetherapy2.Genomics3.Proteomics4.Antibacterials5.Drugtargets1.2.3.4.5.6.7.“”“”1.2.3.4.•–––••••••••••1234“”“”“”1.10150“”“”2100253“”“”2.3.60“”“”“”“”4.20305.510